Health

Concord Medical reports financial decline in first half of 2024

Article Image

Concord Medical Services Holdings (NYSE:CCM), a leading healthcare provider in China specializing in cancer treatment, has released its unaudited financial results for the first half of 2024, revealing a significant downturn in revenues and increased losses.

For the six months ending June 30, 2024, Concord Medical reported total net revenues of RMB218.8 million (approximately US$30.1 million), a stark decline of 23.1% from RMB284.5 million recorded in the same period of 2023.

The company also reported a widening gross loss of RMB41.6 million (US$5.7 million) for the first half of 2024, deepening from a gross loss of RMB37.4 million in the previous year.

The gross loss margin worsened, reaching 19% compared to 13.2% in the first half of 2023.

During the period under review, the net loss attributable to ordinary shareholders also increased significantly, totalling RMB172.3 million (US$23.7 million) compared to a net loss of RMB91 million in the first half of 2023.

Despite the financial setbacks, adjusted EBITDA (a non-GAAP financial measure) remained relatively stable at a negative RMB 148 million (US$20.4 million), only marginally improved from negative RMB148.4 million in the first half of last year.

Disclaimer
Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.
Publisher
Grafa